Vistusertib
Vistusertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against serine/threonine-protein kinase mTOR.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | 1 | 4 | — | — | — | 5 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 3 | — | — | — | 5 |
| Neoplasms | D009369 | C80 | 2 | 3 | — | — | — | 4 | |
| Triple negative breast neoplasms | D064726 | 3 | 2 | — | — | — | 3 | ||
| Adenocarcinoma | D000230 | — | 2 | — | — | — | 2 | ||
| Squamous cell neoplasms | D018307 | 1 | 2 | — | — | — | 2 | ||
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 1 | 1 | — | — | — | 2 | |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 2 | — | — | — | 2 |
| Small cell lung carcinoma | D055752 | 1 | 2 | — | — | — | 2 | ||
| Meningioma | D008579 | EFO_0003098 | D32.9 | — | 2 | — | — | — | 2 |
Show 7 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VISTUSERTIB |
| INN | vistusertib |
| Description | Vistusertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against serine/threonine-protein kinase mTOR. |
| Classification | Small molecule |
| Drug class | serine/threonine kinase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1 |
Identifiers
| PDB | — |
| CAS-ID | 1009298-59-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2336325 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 0BSC3P4H5X (ChemIDplus, GSRS) |
Target
Agency Approved
MTOR
MTOR
Organism
Homo sapiens
Gene name
MTOR
Gene synonyms
FRAP, FRAP1, FRAP2, RAFT1, RAPT1
NCBI Gene ID
Protein name
serine/threonine-protein kinase mTOR
Protein synonyms
FK506 binding protein 12-rapamycin associated protein 2, FK506-binding protein 12-rapamycin complex-associated protein 1, FKBP-rapamycin associated protein, FKBP12-rapamycin complex-associated protein, FKBP12-rapamycin complex-associated protein 1, Mammalian target of rapamycin, Mechanistic target of rapamycin, mechanistic target of rapamycin (serine/threonine kinase), mTOR, Rapamycin and FKBP12 target 1, rapamycin associated protein FRAP2, Rapamycin target protein 1
Uniprot ID
Mouse ortholog
Mtor (56717)
serine/threonine-protein kinase mTOR (Q9JLN9)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 380 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
9 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more